Arq. Bras. Cardiol. 2019; 113(6): 1121-1127
Nrf2, NF-?B and PPAR?/? mRNA Expression Profile in Patients with Coronary Artery Disease
DOI: 10.5935/abc.20190125
This Original Articles is referred by the Short Editorial "PPARβ/δ: Benefits in Coronary Artery Disease and Beyond".
Background:
Oxidative stress and inflammation are present in coronary artery disease (CAD) and are linked to the activation of the transcription nuclear factor kappa B (NF-?B). To attenuate these complications, transcription factors like nuclear factor erythroid 2-related factor 2 (Nrf2) and peroxisome proliferator-activated receptor-?/? (PPAR?/?) can be activated to inhibit NF-?B. However, the available data on expression of NF-?B, Nrf2 and PPAR?/? in CAD patients are limited.
Objective:
To evaluate the expression of the transcription factors NF-?B and Nrf2 and PPAR??/?? in CAD patients.
Methods:
Thirty-five patients (17 men, mean age 62.4 ? 7.55 years) with CAD and twelve patients (5 men, mean age 63.50 ? 11.46 years) without CAD were enrolled. Peripheral blood mononuclear cells (PBMCs) were isolated and processed for mRNA expression of Nrf2, NF-?B, NADPH: qui oxidoreductase 1 (NQO1) and PPAR?/? mRNAs using quantitative real-time polymerase chain reaction (qPCR). p < 0.05 was considered statistically significant.
Results:
There was no difference in the mRNA expressions of Nrf2 (1.35 ? 0.57), NF-?B (1.08 ? 0.50) or in the antioxidant enzyme NQO1 (1.05 ? 0.88) in the CAD group compared to the group without CAD (1.16 ? 0.76, 0.95 ? 0.33, 0.81 ? 0.55, respectively). However, PPAR?/? was highest expressed in the CAD group (1.17 ? 0.86 vs. 0.56 ? 0.34, p = 0.008).
Conclusion:
The main finding of this study was the PPAR?/? being more expressed in the PBMC of patients with CAD compared to the control group, whereas no differences were observed in Nrf2 or NF-?B mRNA expressions.
1,016